¸Þµð¾÷

´ëÇк´¿ø Çѹ溴¿ø
Á¾ÇÕº´¿ø ³ëÀκ´¿ø
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹Á¤º¸
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ëºÐ¾ç¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
¸ÞµðÅå
´ëÇк´¿ø Á¾ÇÕº´¿ø Çѹ溴¿ø Ä¡°úº´¿ø ÇÑÀÇ¿ø ³ëÀÎÀü¹®º´¿ø º¸°Ç¼Ò
¼­¿ï ºÎ»ê ÀÎõ ´ë±¸ ´ëÀü ±¤ÁÖ ¿ï»ê °æ±â °­¿ø ÃæºÏ Ãæ³² °æºÏ °æ³² ÀüºÏ Àü³² Á¦ÁÖ ¼¼Á¾
Ä¡°ú ¾È°ú ÇǺΰú ¼ºÇü¿Ü°ú »êºÎÀΰú ºñ´¢±â°ú ¿Ü°ú ³»°ú Á¤Çü¿Ü°ú À̺ñÀÎÈÄ°ú ¼Ò¾Æ°ú ¾à±¹

¸ñ·Ï ¼öÁ¤ »èÁ¦

´ëÇÑÀü¸³¼±ÇÐȸ The 3rd Korean Prostate Society Prostate Cancer Working Group Symposium : 2024-05-11

ÃßõÇϱâ
¿¬¼ö°­Á À̹øÁÖ BEST
 

´ëÇÑÀü¸³¼±ÇÐȸ The 3rd Korean Prostate Society Prostate Cancer Working Group Symposium : 2024-05-11
±³À°ÀÏÀÚ : 2024-05-11
±³À°Àå¼Ò : ´õÄÉÀÌÈ£ÅÚ ¼­¿ï ±Ý°­È¦

±³À°ÁÖÁ¦ : The 3rd Korean Prostate Society Prostate Cancer Working Group Symposium

ÁÖÃÖ±â°ü : ´ëÇÑÀü¸³¼±ÇÐȸ
´ã´çÀÚ : ±è¹ÎÈñ
¿¬¶ôó : 010-8584-0193  

À̸ÞÀÏ : gaonpco@gaonpco.com

±³À°Á¾·ù : ºñ´¢ÀÇÇаú, ÀÇÇб³À°

Âü¼®¿¹»óÀÎ : 100¸í
Èñ¸ÁÆòÁ¡ : 1Á¡

Áö¿ª : ¼­¿ïƯº°½Ã
±³À°½Ã°£ : 3 ½Ã°£ 30ºÐ

¼¼ºÎ¼ö°­·á : 30,000¿ø  

ºñ°í »çÀüµî·Ï Àü¹®ÀÇ 2¸¸¿øÀü°øÀÇ 1¸¸¿ø ÇöÀåµî·ÏÀü¹®ÀÇ 3¸¸¿øÀü°øÀÇ 2¸¸¿ø


±¸ºÐ ¿ùÀÏ °­ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °­»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ

±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°­È¦ 13:00~13:15 Locally advanced cancer (very high-risk or N1) in the PSMA era Á¶Á¤±â(ÇѾçÀÇ´ë)

Åä·Ð 05¿ù 11ÀÏ ±Ý°­È¦ 13:15~13:45 Panel discussion ±èÅûó(°í½ÅÀÇ´ë)

±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°­È¦ 13:45~14:00 Tactics of ADT administration - continous vs. intermittent ÀÌÇйÎ(¼­¿ïÀÇ´ë)

Åä·Ð 05¿ù 11ÀÏ ±Ý°­È¦ 14:00~14:30 Panel discussion ±èº´ÈÆ(°è¸íÀÇ´ë)

±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°­È¦ 14:50~15:05 Treatment choice following doublet/triplet therapy for mHSPC ¹ÚÁ¾¿í(¿øÀڷº´¿ø)

Åä·Ð 05¿ù 11ÀÏ ±Ý°­È¦ 15:05~15:35 Panel discussion Á¶¹®±â(¿øÀڷº´)

±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°­È¦ 15:35~15:50 The positioning of olaparib/abiraterone within mCRPC sequencing ÇÑÇöÈ£(¿¬¼¼ÀÇ´ë)

Åä·Ð 05¿ù 11ÀÏ ±Ý°­È¦ 15:50~16:20 Panel discussion Á¤Àç½Â(ÀÎÁ¦ÀÇ´ë)

±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°­È¦ 16:20~16:35 Apalutamide rash prevalence study: Updated results ±è¿øÅÂ(ÃæºÏÀÇ´ë)

±³À°½Ã°£ 05¿ù 11ÀÏ ±Ý°­È¦ 16:35~16:50 PSMA theranostics for prostate cancer ¼­¹Î¼®(¼­¿ïÀÇ´ë)

 

ÆÄ¿ö¸µÅ© ±¤°íµî·Ï
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
¸Þµð¾÷
" ´ëÇÑÀü¸³¼±ÇÐȸ The 3rd Korean Prostate Society Prostate Cancer Working Group Symposium : 2024-05-11""ÀÇ ÀÌ¿ëÈı⳪ Ãßõ´ñ±ÛÀ» ³²°Ü À¯¿ëÇÑ Á¤º¸·Î °øÀ¯ÇսôÙ. ^^
¡å
ÀÌ °Ô½Ã¹°À» ÃßõÇÕ´Ï´Ù.
 
¸ñ·Ï ¼öÁ¤ »èÁ¦
ÀÌÀü±Û ¸¸¼ºÆó¼â °ü»óµ¿¸Æ ÁßÀç½Ã¼ú¿¬±¸È¸ The 23rd K-CTO(Korean Chronic Total Occlusion Club) Live Demonstration : 2024-05-11
´ÙÀ½±Û 2024 ´ëÇÑõ½Ä¾Ë·¹¸£±âÇÐȸ Ãá°èÇмú´ëȸ(2ÀÏÂ÷) : 2024-05-11
¹øÈ£ Á¦¸ñ Ãßõ Á¶È¸ µî·ÏÀÏ
20837 ±¤ÁÖ 2024 Çѱ¹¸Á¸·ÇÐȸ ÇÏ°èÇмú´ëȸ(1ÀÏÂ÷) : 2024-06-21 0 58 2024-05-27
20836 ¼­¿ï 2024³â °áÇÙ°ü¸®±³À° 2±â(2ÀÏÂ÷) : 2024-06-21 0 43 2024-05-27
20835 ºÎ»ê ´ëÇѳ»°úÀÇ»çȸ 2024³â Á¦ 1ȸ ³»½Ã°æ Áý´ãȸ : 2024-06-21 0 58 2024-05-27
20834 ¼­¿ï ¼¼ºê¶õ½ºº´¿ø (¿Â¶óÀÎ)¾È°ú ±Ý¿äÁý´ãȸ : 2024-06-21 0 36 2024-05-27
20833 ¼­¿ï ´ëÇѳúÀüÁõÇÐȸ 29rd KOREAN EPILEPSY CONGRESS (2024 KEC) 1ÀÏÂ÷ : 2024-06-21 0 80 2024-05-27
20832 ¼­¿ï Á¦8Â÷ µµºÀ±¸ÀÇ»çȸ Çмú¼¼¹Ì³ª(½ÉÇ÷°üÁúȯ ȯÀÚÀÇ ÀÌ»óÁöÁúÇ÷Áõ Ä¡·á, ºÒ¸éÁõ, Ä¡¸Å¾à¹°Ä¡·á, Ç×Ç÷ÀüÁ¦) : 2024-06-21 0 75 2024-05-27
20831 ºÎ»ê 2024³âµµ ºÎ»ê․°æ³²Áö¿ª ÀÇ°ú´ëÇÐ ½ÅÀÓ±³¼ö ¿öÅ©¼ó (2ÀÏÂ÷) : 2024-06-21 0 55 2024-05-27
20830 Á¦ÁÖ ÀÇ·á±â°ü Á¾»çÀÚ ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ±âº»±³À° : 2024-06-21 0 58 2024-05-27
20829 ¼­¿ï 2024³â °áÇÙ°ü¸®±³À° 2±â(1ÀÏÂ÷) : 2024-06-20 0 41 2024-05-27
20828 ºÎ»ê ´ëÇѼҾÆû¼Ò³â°úÇÐȸ ºÎ»êÁöȸ Áý´ãȸ : 2024-06-20 0 49 2024-05-27
20827 ºÎ»ê ´ëÇѾȰúÇÐȸ ºÎ»êÁöȸ Á¦ 510ȸ ÇмúÁý´ãȸ : 2024-06-20 0 60 2024-05-27
20826 ºÎ»ê 2024³âµµ ºÎ»ê․°æ³²Áö¿ª ÀÇ°ú´ëÇÐ ½ÅÀÓ±³¼ö ¿öÅ©¼ó (1ÀÏÂ÷) : 2024-06-20 0 55 2024-05-27
20825 ¼­¿ï (¿Â¶óÀÎ) ´ëÇÑÅëÁõÇÐȸ ¼­¿ïÁöȸ Áý´ãȸ : 2024-06-20 0 45 2024-05-27
20824 ¼­¿ï (¿Â¶óÀÎ) ÀÇ·á±â°ü Á¾»çÀÚ ´ë»ó ¿¬¸íÀÇ·á°áÁ¤Á¦µµ ½ÉÈ­±³À°(¼­½Ä ÀÛ¼º ½ÇÁ¦) : 2024-06-20 0 48 2024-05-27
20823 °æ±â µ¿±¹´ëÇб³ Àϻ꺴¿ø : °ñ°üÀý¿°ÀÇ Áø´Ü ¹× Ä¡·á : 2024-06-19 0 48 2024-05-27
21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30
 
Ä¿¹Â´ÏƼ
°Ô½ÃÆÇ
°Ç°­Á¤º¸
º´¿ø¾à±¹
Èú¸µ½ºÅ丮
Áúº´Á¤º¸
ÀǾàÇ°Á¤º¸
ÀÇÇм­Àû
ÀÓ´ë¸Å¸Å
¿¬¼ö°­ÁÂ
±³À°Á¤º¸
º´¿øȨÆäÀÌÁö
¸ÞµðÅå
ÇÑÀÇ¿ø
¼ºÇü¿Ü°ú
Ä¡°ú
¾È°ú
¿©¼ºº´¿ø
³»°ú
Á¤Çü¿Ü°ú
ÇǺΰú
¼Ò¾Æ°ú
À̺ñÀÎÈÄ°ú
ºñ´¢ÀÇÇаú
¿ä¾çº´¿ø
ÀçÈ°ÀÇÇаú
µ¿¹°º´¿ø
±âŸº´ÀÇ¿ø
Ãë¾÷°ü·Ã
Áö¿ø¼­¾ç½Ä
¼­·ù¾ç½Ä
¸Þµð¾÷ ¸ð¹ÙÀÏÀ¥
¸Þµð¾÷